BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 52-Week High at $8.75

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price hit a new 52-week high on Thursday . The stock traded as high as $8.75 and last traded at $8.74, with a volume of 316452 shares changing hands. The stock had previously closed at $8.55.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Barclays raised their price target on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Stock Performance

The company has a market capitalization of $1.79 billion, a P/E ratio of -8.12 and a beta of 1.88. The business’s fifty day simple moving average is $7.33 and its 200-day simple moving average is $6.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. The company’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.24) EPS. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.65 EPS for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Amy E. Mckee sold 8,600 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the sale, the director now directly owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Machelle Sanders sold 4,689 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the completion of the transaction, the director now owns 27,742 shares of the company’s stock, valued at approximately $166,452. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Amy E. Mckee sold 8,600 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the sale, the director now directly owns 27,831 shares in the company, valued at $175,891.92. The disclosure for this sale can be found here. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. CWM LLC raised its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,772 shares during the period. Signaturefd LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares during the last quarter. Quarry LP bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $54,000. Seven Eight Capital LP bought a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $57,000. Finally, Natixis grew its holdings in BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 9,350 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.